These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38647526)

  • 1. A Nanopore Sequencing-based Pharmacogenomic Panel to Personalize Tuberculosis Drug Dosing.
    Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
    Am J Respir Crit Care Med; 2024 Jun; 209(12):1486-1496. PubMed ID: 38647526
    [No Abstract]   [Full Text] [Related]  

  • 2. A Nanopore sequencing-based pharmacogenomic panel to personalize tuberculosis drug dosing.
    Verma R; da Silva KE; Rockwood N; Wasmann RE; Yende N; Song T; Kim E; Denti P; Wilkinson RJ; Andrews JR
    medRxiv; 2023 Sep; ():. PubMed ID: 37732197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Rapid Pharmacogenomic Assay to Detect
    Verma R; Patil S; Zhang N; Moreira FMF; Vitorio MT; Santos ADS; Wallace E; Gnanashanmugam D; Persing DH; Savic RM; Croda J; Andrews JR
    Am J Respir Crit Care Med; 2021 Dec; 204(11):1317-1326. PubMed ID: 34375564
    [No Abstract]   [Full Text] [Related]  

  • 4. NAT2 genotype guided regimen reduces isoniazid-induced liver injury and early treatment failure in the 6-month four-drug standard treatment of tuberculosis: a randomized controlled trial for pharmacogenetics-based therapy.
    Azuma J; Ohno M; Kubota R; Yokota S; Nagai T; Tsuyuguchi K; Okuda Y; Takashima T; Kamimura S; Fujio Y; Kawase I;
    Eur J Clin Pharmacol; 2013 May; 69(5):1091-101. PubMed ID: 23150149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic Study of Drugs Affecting Mycobacterium tuberculosis.
    Shabani S; Farnia P; Ghanavi J; Velayati AA; Farnia P
    Int J Mycobacteriol; 2024 Apr; 13(2):206-212. PubMed ID: 38916393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rapid Drug Resistance Genotyping Workflow for Mycobacterium tuberculosis, Using Targeted Isothermal Amplification and Nanopore Sequencing.
    Gliddon HD; Frampton D; Munsamy V; Heaney J; Pataillot-Meakin T; Nastouli E; Pym AS; Steyn AJC; Pillay D; McKendry RA
    Microbiol Spectr; 2021 Dec; 9(3):e0061021. PubMed ID: 34817282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proposal for an individualized pharmacogenetic-guided isoniazid dosage regimen for patients with tuberculosis.
    Jung JA; Kim TE; Lee H; Jeong BH; Park HY; Jeon K; Kwon OJ; Ko JW; Choi R; Woo HI; Koh WJ; Lee SY
    Drug Des Devel Ther; 2015; 9():5433-8. PubMed ID: 26491254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetic Analysis of Isoniazid among Pulmonary Tuberculosis Patients from China.
    Jing W; Zong Z; Tang B; Wang J; Zhang T; Wen S; Xue Y; Chu N; Zhao W; Huang H
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31907179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
    Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
    Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of N-acetyltransferase 2 (NAT2) genotype/single nucleotide polymorphisms on clearance of isoniazid in tuberculosis patients: a systematic review of population pharmacokinetic models.
    Thomas L; Raju AP; Chaithra ; M SS; Varma M; Saravu K; Banerjee M; Sv CS; Mallayasamy S; Rao M
    Eur J Clin Pharmacol; 2022 Oct; 78(10):1535-1553. PubMed ID: 35852584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a limited sampling strategy for the estimation of isoniazid exposure considering N-acetyltransferase 2 genotypes in Korean patients with tuberculosis.
    Lee J; Choi G; Yang S; Ha JE; Kim ES; Park JS; Lee K; Song J; Lee JH; Lee JI
    Tuberculosis (Edinb); 2021 Mar; 127():102052. PubMed ID: 33548864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The role of pharmacogenomics in the tuberculosis treatment regime].
    Guio H; Levano KS; Sánchez C; Tarazona D
    Rev Peru Med Exp Salud Publica; 2015 Oct; 32(4):794-800. PubMed ID: 26732931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis.
    Cho YS; Jang TW; Kim HJ; Oh JY; Lee HK; Park HK; Ghim JL; Long NP; Park Y; Choi YK; Phuong NTT; Shin JG;
    J Clin Pharmacol; 2021 Dec; 61(12):1567-1578. PubMed ID: 34157153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PBPK Analysis to Study the Impact of Genetic Polymorphism of NAT2 on Drug-Drug Interaction Potential of Isoniazid.
    Balhara A; Singh S
    Pharm Res; 2021 Sep; 38(9):1485-1496. PubMed ID: 34518943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Genetic Variation of
    Dompreh A; Tang X; Zhou J; Yang H; Topletz A; Adu Ahwireng E; Antwi S; Enimil A; Langaee T; Peloquin CA; Court MH; Kwara A
    Antimicrob Agents Chemother; 2018 Mar; 62(3):. PubMed ID: 29263072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy, safety, and pharmacokinetics of isoniazid affected by NAT2 polymorphisms in patients with tuberculosis: A systematic review.
    Surarak T; Chumnumwat S; Nosoongnoen W; Tragulpiankit P
    Clin Transl Sci; 2024 Apr; 17(4):e13795. PubMed ID: 38629592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of a Pharmacogenomic Test for Stratified Isoniazid Dosing in Treatment of Active Tuberculosis.
    Rens NE; Uyl-de Groot CA; Goldhaber-Fiebert JD; Croda J; Andrews JR
    Clin Infect Dis; 2020 Dec; 71(12):3136-3143. PubMed ID: 31905381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic testing for NAT2 genotypes in a Tanzanian population across the lifespan to guide future personalized isoniazid dosing.
    Masiphephethu MV; Sariko M; Walongo T; Maro A; Mduma D; Gratz J; Alshaer M; Peloquin CA; Mduma E; Mpagama SG; Thomas T; Houpt ER; Traore A; Bessong P; Heysell SK; Operario DJ
    Tuberculosis (Edinb); 2022 Sep; 136():102246. PubMed ID: 35961094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of novel
    Valafar F; Ramirez-Busby SM; Torres J; Paul LV; Rodwell TC; Victor TC; Rodrigues C; Gler MT; Crudu V; Catanzaro T
    Int J Mycobacteriol; 2015 Mar; 4(Suppl 1):51-52. PubMed ID: 27695670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.